据证交会申报,CEO和两名顶尖执行官于2026年1月出售了价值超过380万美元的股票。 CEO and two top executives sold shares worth over $3.8 million in January 2026, according to SEC filings.

2026年1月13日,学者Rock(NASDAQ:SRRK)首席执行官David Hallal、COO Keith Woods和CFO Vikas Sinha各自以平均价格42.70美元出售公司股票股份,总额分别约为245万美元、715 054美元和715 439美元。 On January 13, 2026, Scholar Rock (NASDAQ:SRRK) CEO David Hallal, COO Keith Woods, and CFO Vikas Sinha each sold shares of the company’s stock at an average price of $42.70, totaling approximately $2.45 million, $715,054, and $715,439 respectively. 这些交易分别减少了其所有权股份3.59%、2.79%和2.79%。 The transactions reduced their ownership stakes by 3.59%, 2.79%, and 2.79%, respectively. 销售情况在证交会的申报中披露。 The sales were disclosed in SEC filings. 学者Rock是一家临床阶段生物技术公司,为涉及增长因素的疾病发展蛋白质治疗,它报告每季度每股损失0.90美元,略低于估计数。 Scholar Rock, a clinical-stage biotech firm developing protein therapeutics for diseases involving growth factors, reported a quarterly loss of $0.90 per share, slightly below estimates. 其主要候选人SRK-015(acception)正因治疗脊椎肌肉萎缩而接受调查。 Its lead candidate, SRK-015 (appercept), is under investigation for treating spinal muscular atrophy. 该公司的市场上限为47.5亿美元,P/E的负比率为14.77,分析师维持“Buy”共识,目标价格为50.14美元。 The company has a market cap of $4.75 billion, a negative P/E ratio of -14.77, and analysts maintain a "Buy" consensus with a $50.14 target price.